New EU Approvals
The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with two new products including Astellas Pharma's Xospata (gilteritinib) for treating relapsed or refractory acute myeloid leukemia. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
You may also be interested in...
Novartis’s siRNA for lowering cholesterol was also among the 10 new medicines that the European Medicines Agency this week said should be approved in the EU.
The developers of three drugs are hoping the European Medicines Agency will decide that their products merit fast-tracking when they are submitted for review for potential pan-EU approval.
Hot on the heels of announcing it was joining Project Orbis, the UK drug regulator, the MHRA, now says it will join another international collaboration that allows drug companies to submit medicines for review by several countries at the same time.